Posted by Michael Wonder on 14 Nov 2025
Arcutis Canada announces Health Canada approval of Zorvye 0.3% topical foam, the first steroid-free topical foam for scalp and body psoriasis, for adults and adolescents ages 12 and older
13 November 2025 - Approval supported by pivotal Phase 3 and Phase 2 data demonstrating rapid improvement in skin clearance and itch relief.
Arcutis Canada is pleased to announce that Health Canada has approved Zorvye (roflumilast foam 0.3%) for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years of age and older.
